Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, dose-escalation study of SB-485232. Subjects will receive
SB-485232 administered as subcutaneous injections daily for 14 days. Dose escalation
(enrollment into the next cohort) cannot occur until all three subjects have completed the
previous cohort; 5 doses will be tested. An additional dosing regimen has been added to
evaluate higher doses given twice weekly for 7 weeks. Therefore, the full evaluation period
for each patient will extend out to approximately eleven weeks after the first day of
SB-485232 dosing.